FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	-		_	-			_		-
W	as	hin	gto	n,	D	.C.	2	054	9

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-0362										
OMB Number: 3235-036 Estimated average burden										
hours per respons	e· 10									

3 Holdings Rep	orted.																
4 Transactions	Reported.	Filed									34						
Name and Address of Reporting Person* Francois Cedric				2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS]						(Cr	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC.				3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2021)	X Officer (give title Other (specify below) below) Chief Executive Officer						
(Street) WALTHAM MA 02451				4. If Amendment, Date of Original Filed (Month/Day/Year)					Lin	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(51											<u>.</u>						
				_		quire						-					
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	Execution Date, if any		Transaction Code (Instr.		4. Securities Acquired (A) or Dispo			sposed	Securities Beneficially		Ownership Form: Direct		7. Nature of Indirect Beneficial Ownership		
			(,				Amoun	t	(A) or (D) Price			Issuer's Fiscal		Indirect (I)		(Instr. 4)	
Common Stock		06/16/2021			G		80,	000	D	D \$0.00		854,243])		
Common Stock												234,411				ee ootnote ⁽¹⁾	
Common Stock												300,000				ee ootnote ⁽²⁾	
	Та												d				
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	of Deriv Secu Acqu (A) o Disp of (D (Inst	vative urities uired or osed o) r. 3, 4	Expi (Mor	Expiration Date			3 and 4) Amou		Derivative Security (Instr. 5) Benefic Owned Followii Reporte Transac		ve es ally ng d tion(s)	Form: Direct (D) or Indirec	Beneficial Ownership (Instr. 4)	
	4 Transactions and Address of his Cedric (Fin ELLIS PHA TH AVENU (AM M. (St. Security (Instr.) 1 Stock a Stock a Stock conversion or Exercise Price of Derivative	(First) (ELLIS PHARMACEUTIC TH AVENUE, 3RD FLOO (AM MA (State) Table Security (Instr. 3) 1 Stock 1 Stock 2. Conversion or Exercise Price of Derivative (Month/Day/Year)	A Transactions Reported. A Transactions Reporting Person* Dis Cedric (First) (Middle) ELLIS PHARMACEUTICALS, INC. TH AVENUE, 3RD FLOOR Table I - Non-Derivation Date (Month/Day/Year) A Stock Table II - Derivation Or Exercise Price of Derivative 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) A Deemed Execution Date, if any (Month/Day/Year)	A Transactions Reported. Filed pursuant to Sor Section 3 Ind Address of Reporting Person* Ind Address of	A Transactions Reported. Filed pursuant to Section 30(h) or Section 30(h)	4 Transactions Reported. Filed pursuant to Section 16(a) or Section 30(h) of the land Address of Reporting Person* Dis Cedric (First) (Middle) ELLIS PHARMACEUTICALS, INC. TH AVENUE, 3RD FLOOR A. If Amendment, Date of Security (Instr. 3) Table I - Non-Derivative Securities Accurrity (Instr. 3) 2. Transaction Date (Month/Day/Year) if any (Month/Day/Year) A Stock Table II - Derivative Securities Acqueries (e.g., puts, calls, warrants, (Month/Day/Year) of Derivative Price of Derivative (Month/Day/Year) 2. Transaction Date (Instr. 3) 3. Transaction Date (Instr. 3) 4. Transaction Code (Instr. 3) 5. Number of Derivative Securities Acqueried (Month/Day/Year) 4. Transaction Code (Instr. 3) 5. Number of Derivative Securities Acqueried (Month/Day/Year) 7. Number of Derivative Securities Acqueried (Month/Day/Year) 8. Number of Derivative Securities Acqueried (Instr. 3) 8. Number of Derivative Securities Acqueried (Month/Day/Year) 8. Number of Derivative Securities Acqueried (Month/Day/Year) 8. Number of Derivative Securities Acqueried (Month/Day/Year)	Filed pursuant to Section 16(a) of the or Section 30(h) of the Invest of Section 30(h) of the	A Transactions Reported. Filed pursuant to Section 16(a) of the Security or Section 30(h) of the Investment Consection 3 (h) of the Investment Consection 3	A Transactions Reported. Filed pursuant to Section 16(a) of the Securities Exchor Section 30(h) of the Investment Company Action Section 30(h) of Investment Company Action Section 30(h)	A Transactions Reported. Filed pursuant to Section 16(a) of the Securities Exchange A or Section 30(h) of the Investment Company Act of 19 and Address of Reporting Person* Indicators of Reporting	A Transactions Reported. Filed pursuant to Section 16(a) of the Securities Exchange Act of 19 of Section 30(h) of the Investment Company Act of 1940 Apellis Pharmaceuticals, Inc. [APLS] 2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS] 3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) AMM MA 02451 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Bene (Month/Day/Year) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Amount (A) or Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired, Disposed of, or Benerical Stock Table II - Derivative Securities Acquired Stock Table II - Derivative Securities Acquired Stock Table II - Derivative Security (Month/Day/Year) Amount Stock Securities Acquired (Month/Day/Year) Amount Stock Securities Acquired (Month/Day/Year) Amount Stock Securities Acquired (Month/Day/Year) Securities Acquired (Month/Day/Year) Amount Stock Securities Acquired (Month/Day/Year) Securities Acquired (Month/Day/Year)	A Transactions Reported. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1934 or Section 30(h) of the Investment Company Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Apellis Pharmaceuticals, Inc. [APLS] S. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2021 Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficial Execution Date (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficial Security (Instr. 3) Date (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficial Security (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficial Security (Lapped Code (Instr. 6)) Table II - Derivative Securities Acquired, Disposed of, or Beneficial Security (Lapped Code (Instr. 6)) Table II - Derivative Securities Acquired, Disposed of, or Beneficial Securities (Lapped Code (Instr. 6)) Table II - Derivative Securities Acquired, Disposed of, or Beneficial Securities (Lapped Code (Instr. 6)) Table II - Derivative Securities Acquired (Instr. 6) Table II - Derivative Securities Acquired (Instr. 7) Table II	Filed pursuant to Section 15(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Address of Reporting Person* is Cedric (First) (Middle) ELLIS PHARMACEUTICALS, INC. TH AVENUE, 3RD FLOOR AM MA 02451 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owner (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owner (and it any (Month/Day/Year)) 1 Stock Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Conversion Of Exercision Date (a.g., puts, calls, warrants, options, convertible securities) 2. Transaction Date (Month/Day/Year) 3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 4. If Amendment, Date of Original Filed (Month/Day/Year) 5. Anount (A) or Disposed of (D) (Instr. 3, 4 and 5) Amount (A) or Price Veser (b.g., puts, calls, warrants, options, convertible securities) 2. Transaction Conversion Objective Securities Acquired, Disposed of, or Beneficially Owned of Conversion Objective Securities (A) or Disposed of Securities Securities (Beneficially Owned of Conversion Objective Securities (A) or Disposed of Securities Securities (Check all approach (Check al	A transactions Reported. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 20(h) of the Investment Company Act of 1934 or Section 30(h) of the Investment Company Act of 1934 or Section 30(h) of the Investment Company Act of 1934 or Section 30(h) of the Investment Company Act of 1934 or Section 30(h) of the Investment Company Act of 1934 S. Relationship of Reported Apellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reported A pellis Pharmaceuti	4 Transactions Reported. Filed pursuant to Section 15(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Apellis Pharmaceuticals, Inc. [APLS] S. Relationship of Reporting Person is Cedric (First) (Middle) Apellis Pharmaceuticals, Inc. [APLS] 3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) IZ/31/2021 Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Securities Fiscal Amount (A) or Price (Gerg. Price (Instr. 3)) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securi	A Transactions Reported. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(f) of the investment Company Act of 1940 Address of Reporting Person' is Cedric (First) (Middle) BELLIS PHARMACEUTICALS, INC. TH AVENUE, 3RD FLOOR (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Beautiful (Month/Day/Year) (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Beautiful (Month/Day/Year) (Month/Day/Year) (Stock 06/16/2021 G 8 80,000 D \$0.00 854,243 D 15. Stock Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrantso (Bonth) Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	

Explanation of Responses:

- 1. The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.
- 2. The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.

Remarks:

/s/ David Watson, attorney-infact for Cedric Francois

02/10/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.